Iovance Biotherapeutics

Traded on the St. Petersburg Stock Exchange
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer. The company was founded in 2007 as Genesis Biopharma.
Iovance Biotherapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Iovance Biotherapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q1 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Iovance Biotherapeutics cash flows

Report period2018 2019 2020 2021 2022 Q1 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Iovance Biotherapeutics multipliers

Report period2018 2019 2020 2021 2022 Q1 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Iovance Biotherapeutics profitability

Report period2018 2019 2020 2021 2022 Q1 23 TTM
ROA
ROE
ROS
Iovance Biotherapeutics assets
Iovance Biotherapeutics cash flows

Iovance Biotherapeutics shares

TickerNameTypeNominal valueISINPrice
IOVA:USIovance Biotherapeutics, Inc.Common share-US4622601007$12.28
Iovance Biotherapeutics news
06.05.2022
Iovance Biotherapeutics' GAAP loss for 3 months of 2022 was $91.607 million, up 21.4% from $75.449 million in the previous year.
Source: {source} pictogram ir.iovance.com
Pictogram next
25.02.2022
Iovance Biotherapeutics' GAAP loss for 2021 was $342.252 million, up 31.8% from $259.581 million in the previous year.
Source: {source} pictogram ir.iovance.com
Pictogram next
05.11.2021
Iovance Biotherapeutics reported a GAAP loss of $242.922 million for 9M 2021, up 27.1% from $191.184 million in the previous year.
Source: {source} pictogram ir.iovance.com
Pictogram next
06.08.2021
Iovance Biotherapeutics' GAAP loss for six months of 2021 was $156.8 million, up 18.2% from $132.613 million in the prior year.
Source: {source} pictogram ir.iovance.com
Pictogram next
All Iovance Biotherapeutics news
General information
Company nameIovance Biotherapeutics
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070 6502607120
Mailing address999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070
Websitewww.iovance.com
Information disclosurewww.sec.gov